Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

Representative Robert Bresnahan, Jr. recently sold Danaher shares worth between $1,001 and $15,000 on May 15th. He also made ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

The new SCIEX OS software version 4.0 is the latest evolution of its powerful software platform. This new Microsoft Windows 11 compatible release drives operability enhancements with speed and ...

Capital snapped up $1.73 million worth of Danaher shares, joining a crowd of institutional investors stacking their chips on ...

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at ...

The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

"Our partnership with Danaher and [Danaher subsidiary] Leica Biosystems underscores our commitment to pioneering AI-based diagnostics which can improve patient selection, and our belief that ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...